Related Experiment Video

Updated: May 25, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of

Dana Haddad1, Nanhai Chen, Qian Zhang

  • 1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Annals of Surgical Oncology
|January 20, 2012
PubMed
Abstract

Insights

A novel oncolytic vaccinia virus, GLV-1h151, effectively targets and destroys various cancer cells. This virus demonstrated significant tumor regression in preclinical models with a favorable safety profile, offering a promising new cancer therapy.

Area of Science:

  • Oncolytic virotherapy
  • Cancer research
  • Viral oncology

Background:

  • Replication-competent oncolytic viruses show promise for cancer treatment.
  • A novel vaccinia virus, GLV-1h151, was developed with enhanced cancer specificity and detectability.

Purpose of the Study:

  • To evaluate the efficacy of GLV-1h151 against diverse human cancers.
  • To assess the safety of GLV-1h151 in preclinical cancer models.

Main Methods:

  • GLV-1h151 was genetically modified for specificity and detection (GFP).
  • Cytotoxicity assays were performed on breast, lung, pancreatic, and colorectal cancer cell lines.
  • In vivo studies involved administering GLV-1h151 to pancreatic cancer xenografts in mice.

Main Results:

  • GLV-1h151 demonstrated effective infection, replication, and cancer cell killing.
  • Fluorescence imaging confirmed dose-dependent virus replication.
  • Intravenous and intratumoral administration led to significant tumor regression (P < 0.001) with a good safety profile.

Conclusions:

  • GLV-1h151 is a potent oncolytic agent against various cancers in vitro and in vivo.
  • The virus exhibits a favorable safety profile and can be tracked via optical imaging.
  • GLV-1h151 represents a potential new therapeutic strategy for cancer treatment.

More Related Videos

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...